• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

作者信息

Zhao Sizheng Steven, Harrison Stephanie R, Thompson Ben, Yates Max, Eddison Joe, Chan Antoni, Clarke Nick, Corp Nadia, Davis Charlotte, Felix Lambert, Flora Kalveer, Gregory William J, Jones Gareth T, Lamb Christopher A, Marzo-Ortega Helena, Murphy Daniel J, Petrushkin Harry, Sandhu Virinderjit, Sengupta Raj, Siebert Stefan, Van Der Windt Danielle A, Webb Dale, Yiu Zenas Z N, Gaffney Karl

机构信息

Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.

出版信息

Rheumatology (Oxford). 2025 Jun 1;64(6):3242-3254. doi: 10.1093/rheumatology/keaf089.

DOI:10.1093/rheumatology/keaf089
PMID:40199504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12107049/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8af/12107049/36dffb304ab6/keaf089f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8af/12107049/36dffb304ab6/keaf089f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8af/12107049/36dffb304ab6/keaf089f1.jpg

相似文献

1
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.2025年英国风湿病学会关于使用生物制剂和靶向合成改善病情抗风湿药治疗中轴型脊柱关节炎的指南。
Rheumatology (Oxford). 2025 Jun 1;64(6):3242-3254. doi: 10.1093/rheumatology/keaf089.
2
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.执行摘要：2025年英国风湿病学会关于使用生物制剂和靶向合成改善病情抗风湿药治疗中轴型脊柱关节炎的指南。
Rheumatology (Oxford). 2025 Jun 1;64(6):3234-3241. doi: 10.1093/rheumatology/keaf090.
3
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.使用生物制剂和靶向合成改善病情抗风湿药治疗中轴型脊柱关节炎：英国风湿病学会指南范围
Rheumatol Adv Pract. 2023 May 15;7(2):rkad039. doi: 10.1093/rap/rkad039. eCollection 2023.
4
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis.泛美风湿病协会联盟关于治疗中轴型脊柱关节炎的建议。
Nat Rev Rheumatol. 2023 Nov;19(11):724-737. doi: 10.1038/s41584-023-01034-z. Epub 2023 Oct 6.
5
Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.在中轴型脊柱关节炎中，无论影像学状态如何，生物制剂的疗效相似：来自英国风湿病学会生物制剂注册处的强直性脊柱炎注册研究的数据。
Rheumatology (Oxford). 2021 Dec 1;60(12):5795-5800. doi: 10.1093/rheumatology/keab070.
6
Comparison of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondyltis from a Single Rheumatology Hospital in Morocco.摩洛哥单家风湿病医院的非放射性轴性脊柱关节炎与强直性脊柱炎的比较。
Curr Rheumatol Rev. 2020;16(3):240-244. doi: 10.2174/1573397115666190222195923.
7
Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.轴性脊柱关节炎中外周关节表现的预测因素及其对 TNF 抑制剂处方模式的影响：来自英国风湿病学会强直性脊柱炎生物制剂登记处的结果。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001206.
8
Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.强直性脊柱炎与非放射学中轴型脊柱关节炎外周及关节外疾病的患病率：一项荟萃分析。
Arthritis Res Ther. 2016 Sep 1;18(1):196. doi: 10.1186/s13075-016-1093-z.
9
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.生物改善病情抗风湿药的疗效与安全性：一项系统性文献综述，为2022年更新的ASAS-EULAR轴性脊柱关节炎管理推荐提供依据
Ann Rheum Dis. 2023 Jan;82(1):130-141. doi: 10.1136/ard-2022-223298. Epub 2022 Oct 21.
10
Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.急性前葡萄膜炎及脊柱关节炎的其他关节外表现。
J Med Life. 2015 Jul-Sep;8(3):319-25.

本文引用的文献

1
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.接受比美吉单抗治疗的中轴型脊柱关节炎患者的低葡萄膜炎发生率：来自 2b/3 期试验的汇总结果。
Ann Rheum Dis. 2024 Nov 14;83(12):1722-1730. doi: 10.1136/ard-2024-225933.
2
Exercise as an anti-inflammatory Therapy in Axial Spondyloarthritis Therapeutic Intervention (EXTASI) study: a randomized controlled trial.轴性脊柱关节炎治疗干预中的运动抗炎疗法（EXTASI）研究：一项随机对照试验。
Rheumatol Adv Pract. 2024 May 11;8(2):rkae062. doi: 10.1093/rap/rkae062. eCollection 2024.
3
Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort.
强直性脊柱炎骶髂关节炎影像学进展 10 年：DESIR 队列研究。
Ann Rheum Dis. 2024 Jun 12;83(7):858-864. doi: 10.1136/ard-2023-225184.
4
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis.生物制剂或靶向合成药物治疗中轴型脊柱关节炎患者葡萄膜炎的发生率：系统评价和网络荟萃分析。
Arthritis Rheumatol. 2024 May;76(5):704-714. doi: 10.1002/art.42788. Epub 2024 Apr 13.
5
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.托法替布在既往使用过生物改善病情抗风湿药的强直性脊柱炎患者中的疗效和安全性：一项事后分析
ACR Open Rheumatol. 2023 Dec;5(12):632-643. doi: 10.1002/acr2.11601. Epub 2023 Sep 29.
6
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.欧洲中轴型脊柱关节炎患者的二线和三线 TNF 抑制剂：疗效和转换原因的影响。
Rheumatology (Oxford). 2024 Jul 1;63(7):1882-1892. doi: 10.1093/rheumatology/kead494.
7
Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis.银屑病在伴有中轴型脊柱关节炎的患者中似乎经常被漏诊。
Arthritis Res Ther. 2023 Aug 9;25(1):145. doi: 10.1186/s13075-023-03119-2.
8
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.2023 年处于临床开发阶段的治疗脊柱关节炎（包括银屑病关节炎）的疾病修正抗风湿药物（DMARDs）：一项试验的系统评价。
RMD Open. 2023 Jul;9(3). doi: 10.1136/rmdopen-2023-003279.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药物治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6.
10
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.使用生物制剂和靶向合成改善病情抗风湿药治疗中轴型脊柱关节炎：英国风湿病学会指南范围
Rheumatol Adv Pract. 2023 May 15;7(2):rkad039. doi: 10.1093/rap/rkad039. eCollection 2023.